Japan-based Takeda Pharmaceutical has revealed results from the primary endpoint analysis of the ongoing pivotal Phase three Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate (TAK-003) that were published in the New England Journal of Medicine, it was reported on Friday.
The company's dengue vaccine candidate indicated protection against virologically-confirmed dengue, the trial primary endpoint, in children ages 4 to 16 years. Vaccine efficacy was 80.2% in the 12-month period after the second dose, which was administered three months after the first dose.
The firm's dengue vaccine candidate was generally well tolerated, and no important safety risks have been observed to date. The observed safety profile was consistent with results reported in earlier studies of TAK-003.1,2,3,4.
The TIDES trial will continue to assess safety and efficacy in study subjects for a total of four and a half years.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV